A great advantage of RNA therapy in SMA compared with other approaches (such as gene therapy) is that the SMN2 gene remains expressed under its own endogenous promoter, subject to its regular turnover, thus obviating the need for transgene introduction. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.